{"ticker": {"uuid": "a2e2b408-81c8-4e45-9b4c-807750556b31", "symbol": "URGN", "name": "UroGen Pharma Ltd", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "URGN stock trades steady as UroGen revenue grows and pipeline advances", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxPUzdKQ3F3dDZEMWV0dnJqVkpSX3NYd25PUkd3dW44NVlnUEV3Q1FfREs4WU1GZzBHTHdENHRYRjNnSGZTV3lYTFNLbkstOWNvMEZ6MTAzUWF2ZkdfampTY0FmWE5Yc2NicXZuZExpMlNDMjdXbEUwenlMbk9VTmg0V0RaY2lNSGt4cGVOZW8tR1ZfWFZERWVhOWRRS2d4d0prOXRzV1NsTTlrWVJ4RG5hbVJoYjR0LVVic21oVk50VDgzaFF0LVFxQg?oc=5", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-21T11:27:30+00:00", "published_display": "21 Jul 2026 11:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What UroGen Pharma (URGN)'s UGN-501 IND Clearance Means For Shareholders", "summary": "UroGen Pharma received IND clearance for UGN-501, an oncolytic virus for non-muscle invasive bladder cancer, allowing a Phase 1 trial to commence. While this expands their pipeline, the company's near-term focus remains on the uptake of ZUSDURI and the regulatory path for UGN-103", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-urgn/urogen-pharma/news/what-urogen-pharma-urgns-ugn-501-ind-clearance-means-for-sha", "source_name": "Simply Wall Street", "published_at": "2026-07-21T05:12:14", "published_display": "21 Jul 2026 05:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of UroGen Pharma Ltd. \u2013 MUN:UR8", "summary": "This article focuses on the \"Price to sales forward\" financial metric for UroGen Pharma Ltd. (MUN:UR8) available on TradingView. It appears to be a financial data snippet or a specific data point rather than a detailed analytical article. The content is primarily a listing of fin", "url": "https://www.tradingview.com/symbols/MUN-UR8/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-21T02:09:58", "published_display": "21 Jul 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of UroGen Pharma Ltd. \u2013 NASDAQ:URGN", "summary": "This article provides a brief financial update for UroGen Pharma Ltd. (NASDAQ: URGN), specifically focusing on its forward price-to-sales ratio. It indicates that the market was closed with no trades recorded at the time of the report. The content appears to be a stub or a placeh", "url": "https://www.tradingview.com/symbols/NASDAQ-URGN/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-21T00:12:14", "published_display": "21 Jul 2026 00:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UroGen Pharma: Reimbursement Is Turning Zusduri Into A Workflow Moat (NASDAQ:URGN)", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxOR1RQLUpKWnAtMHpDcUZuN2tHZzR0SXplS0xWVTVPUDQ4QUttNExwU2xNN1FMUlBocTFTNElrbUZlRU1iWHlnZ2Nnc25lVXFjZ1l0bzltTkNVYnZOTEhPODFOVWdldkRDNHNkTnR3ZmMtaGVuSkdaQWI4MDA1R0x1V3B6a2YyOW5UUklZWE5CempYS3Q3OXYtbWJSMnlQRXgyZWs2Y3BXVmZjWXhm?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-20T18:07:04+00:00", "published_display": "20 Jul 2026 18:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UroGen Pharma (URGN) AGM 2026 Summary", "summary": "UroGen Pharma's 2026 AGM highlighted the successful launch of ZUSDURI, a new FDA-approved bladder cancer treatment, and continued growth of JELMYTO. The meeting also addressed the advancement of pipeline products like UGN-103, UGN-104, and UGN-501, and nominated seven directors f", "url": "https://quartr.com/events/urogen-pharma-ltd-urgn-agm-2026_F3zJeaCg", "source_name": "Quartr", "published_at": "2026-07-20T02:09:58", "published_display": "20 Jul 2026 02:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UroGen Pharma (URGN) Rallies On FDA Clearance As Valuation Questions Grow", "summary": "UroGen Pharma (URGN) has rallied significantly following FDA clearance for its UGN-501, allowing a Phase 1 bladder cancer study. While the stock has seen impressive returns, current analyst narratives suggest it is overvalued at $36.11, despite a Simply Wall St DCF model indicati", "url": "https://www.sahmcapital.com/news/content/urogen-pharma-urgn-rallies-on-fda-clearance-as-valuation-questions-grow-2026-07-18", "source_name": "Sahm", "published_at": "2026-07-19T02:09:59", "published_display": "19 Jul 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What's Driving Investor Interest in UroGen Pharma (URGN) Ahead of Goldman Sachs", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNNEdGU1B4UmE0TUpkZ284Q212QmdqNTlaZkl0WWN1d1pRWFRncXNZbk9XbXRCSWFTc2FIOHhRSEFqYWc5Q25Ta0xTcE40R3Vqa0UxcmhNY09YaXVTZVJvUDR0cTVxai1scjVENTNfM282N3Z4bkNZRU5NOTBLX3JFSGdUY0pHRV8tTTBERXhJXzNNLXkxeDluc3lNcHlERll2NXFrZzd6dWJ4ZVFSclh0V21R?oc=5", "source_name": "Kavout | AI", "published_at": "2026-07-18T14:00:24+00:00", "published_display": "18 Jul 2026 14:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Urogen Pharma stock hits 52-week high at 41.45 USD", "summary": "Urogen Pharma's stock has reached a 52-week high of $41.45, reflecting strong investor confidence and significant year-to-date gains. The company has several positive developments, including an increased price target from Oppenheimer, a new patent for bladder cancer treatment, an", "url": "https://www.investing.com/news/company-news/urogen-pharma-stock-hits-52week-high-at-4145-usd-93CH-4798631", "source_name": "Investing.com", "published_at": "2026-07-18T13:41:46", "published_display": "18 Jul 2026 13:41", "sentiment": "positive", "sentiment_pct": 94, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Short Sellers Are Betting Against UroGen Pharma Stock, But Wall Street Expects 263% Earnings Growth in 2027", "summary": "UroGen Pharma (URGN) has experienced significant stock growth and strong technical indicators, with analysts predicting substantial revenue and earnings increases in the coming years. Despite this positive outlook and five years of revenue growth, the company remains unprofitable", "url": "https://www.barchart.com/story/news/3336887/short-sellers-are-betting-against-urogen-pharma-stock-but-wall-street-expects-263-earnings-growth-in-2027", "source_name": "Barchart.com", "published_at": "2026-07-18T09:15:00", "published_display": "18 Jul 2026 09:15", "sentiment": "positive", "sentiment_pct": 76, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Urogen Pharma stock hits 52-week high at 41.45 USD By Investing.com", "summary": "Urogen Pharma Ltd.'s stock reached a 52-week high of $41.45, now trading just under 1% below its peak with significant year-to-date and six-month returns. This surge follows positive developments including Oppenheimer raising its price target to $50, a patent allowance for bladde", "url": "https://m.za.investing.com/news/stock-market-news/urogen-pharma-stock-hits-52week-high-at-4145-usd-93CH-4374664?ampMode=1", "source_name": "Investing.com South Africa", "published_at": "2026-07-18T00:09:38", "published_display": "18 Jul 2026 00:09", "sentiment": "positive", "sentiment_pct": 94, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "H.C. Wainwright reiterates UroGen Pharma stock rating on patent news", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxOTlBYdmZzYVF6dFdJUE9KSU5waU5MWXotS0NQeEtwaWRVSWljV0VMR3JBRUpnaXpQVkQyREw1NTcwalI0bUZWR285dll3VkFrWXNsU3h1cnQwdlJqaXdLbGtoYjNaY3RHX0txUVpKRUtITGFyMlh6NFdMYmNNMHRoRzZtRTBTN0hmWGEyNkJMMXFQdHVkeDZXNldaOU11SGN3VXdGUjAxVUMwc1JxVFM5X0k0T1U3SXl0ZGlfWGpaWFpyYWR1?oc=5", "source_name": "Investing.com", "published_at": "2026-07-16T11:58:03+00:00", "published_display": "16 Jul 2026 11:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oppenheimer raises UroGen Pharma stock price target to $50 on sales outlook", "summary": "Oppenheimer has increased its price target for UroGen Pharma (NASDAQ:URGN) to $50 from $40, maintaining an Outperform rating, based on increased sales projections for their Jelmyto product. The firm's updated estimates for Jelmyto sales in 2026-28 are $210 million, $448 million, ", "url": "https://www.investing.com/news/analyst-ratings/oppenheimer-raises-urogen-pharma-stock-price-target-to-50-on-sales-outlook-93CH-4795586", "source_name": "Investing.com", "published_at": "2026-07-16T11:58:09", "published_display": "16 Jul 2026 11:58", "sentiment": "positive", "sentiment_pct": 86, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates UroGen Pharma stock rating on patent news By Investing.com", "summary": "H.C. Wainwright has reiterated a Buy rating and a $45.00 price target for UroGen Pharma (NASDAQ:URGN) after the company received a Notice of Allowance for a patent related to treating low-grade intermediate-risk non-muscle-invasive bladder cancer. This patent, supported by data f", "url": "https://m.au.investing.com/news/stock-market-news/hc-wainwright-reiterates-urogen-pharma-stock-rating-on-patent-news-93CH-4536603?ampMode=1", "source_name": "Investing.com Australia", "published_at": "2026-07-16T11:39:29", "published_display": "16 Jul 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UroGen Pharma (URGN) Secures Patent Approval for Bladder Cancer Treatment", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxPTFh2bjZDcWNzaWpGLVc0VlYyM1M4RUkxb2dBT0g1QTlHM1NfUkhoNXdVeUFpOGM3S1k0YmVIeTZNcVBic0dEMFFvUVp6cE9LOTdxU0NVajhtaThaSlpFTld5MmVMLUtCUDFUQUdIM0M0bDI3a2p1U2QwYkd3b2dYX0F4WDlTT25zRzI0aGZiemw0MENlMHpRNDJzRmYzSDNBWDNtSzhWUUxPTG5semdaRTNtOVNBOERyRDk5Nl9FaGswUjlVTHVmU21Vcjg3elpKa1dLYmgzLUtkZUxPeldiMTM0YkU?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-16T10:11:24+00:00", "published_display": "16 Jul 2026 10:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Goldman Sachs Maintains UroGen Pharma Ltd(URGN.US) With Hold Rating, Raises Target Price to $44", "summary": "Goldman Sachs has reiterated its Hold rating on UroGen Pharma Ltd (URGN.US) and has increased its price target for the company's stock to $44. This adjustment reflects a continued neutral stance on the company's prospects while revising the expected valuation upwards.", "url": "https://www.moomoo.com/news/post/73032059/goldman-sachs-maintains-urogen-pharma-ltd-urgnus-with-hold-rating", "source_name": "Moomoo", "published_at": "2026-07-16T01:10:08", "published_display": "16 Jul 2026 01:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UroGen Pharma (URGN) Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary", "summary": "UroGen Pharma (URGN) presented at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026, highlighting its RTGel technology for sustained drug delivery in urothelial cancer. The company discussed the commercial success of its products, JELMYTO and ZUSDURI, with ZUSDURI's", "url": "https://quartr.com/events/urogen-pharma-urgn-guggenheim-securities-emerging-outlook-biotech-summit-2026_F3zJeILb", "source_name": "Quartr", "published_at": "2026-07-15T13:41:46", "published_display": "15 Jul 2026 13:41", "sentiment": "positive", "sentiment_pct": 75, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UroGen patent allowance covers bladder cancer care without tumor resection", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxPdExkdFJxSTdEVlgtVHpLVWtwc296VUJGZmtLdGFIcFlmYlpRbXhwMk1Obm53aklWZ2lPdEdwSjlBWHJHd0U4Vl9acmtZcmNEVE9xNV9DcnF0ZHNjQktZTEJIbTRub21aUFJaVGN5MU9fcl81X3R4b181Z1hPSW1GdW5NM0VzdFhVTHAwcndZNGtyZzJ3NVFSUnQ2cEplS2l6UU9Id2ZyMlc4U0hZN0RaUTBkbWQ2Mzg?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-15T12:00:00+00:00", "published_display": "15 Jul 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UroGen Receives New U.S. Patent Allowance Expected to Provide Protection into July 2044 for ZUSDURI\u2122 and UGN-103", "summary": "UroGen Pharma Ltd. announced it received a U.S. patent allowance extending protection for ZUSDURI\u2122 and investigational UGN-103 into July 2044. The patent covers methods for treating recurrent, low-grade intermediate-risk non-muscle-invasive bladder cancer without transurethral re", "url": "https://www.globenewswire.com/news-release/2026/07/15/3327670/0/en/urogen-receives-new-u-s-patent-allowance-expected-to-provide-protection-into-july-2044-for-zusduri-and-ugn-103.html", "source_name": "GlobeNewswire", "published_at": "2026-07-15T12:15:29", "published_display": "15 Jul 2026 12:15", "sentiment": "positive", "sentiment_pct": 74, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UroGen Announces FDA Clearance of the IND for UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer", "summary": "UroGen Pharma Ltd. announced that the FDA has cleared its Investigational New Drug (IND) application for UGN-501, a next-generation oncolytic virus for non-muscle invasive bladder cancer (NMIBC). This clearance allows the company to initiate a Phase 1 clinical study in Q4 2026 to", "url": "https://biobuzz.io/news/urogen-announces-fda-clearance-of-the-ind-for-ugn-501-an-investigational-next-generation-oncolytic-virus-for-non-muscle-invasive-bladder-cancer/", "source_name": "BioBuzz", "published_at": "2026-07-15T00:15:30", "published_display": "15 Jul 2026 00:15", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UroGen's Chief Medical Officer Sold $400,000 in Stock After a 191% Run", "summary": "UroGen Pharma's Chief Medical Officer, Mark Schoenberg, sold 10,000 shares worth $400,000 as the final transaction of a pre-established 10b5-1 trading plan. Despite the sale, Schoenberg retains a significant stake of nearly $4.8 million in the company. The article notes this tran", "url": "https://finance.yahoo.com/markets/stocks/articles/urogens-chief-medical-officer-sold-183156914.html", "source_name": "Market source", "published_at": "2026-07-13T11:41:25", "published_display": "13 Jul 2026 11:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "UroGen Pharma (URGN) Is Up 5.8% After FDA Clears IND For UGN-501 Phase 1 Trial", "summary": "UroGen Pharma's stock rose 5.8% after the FDA cleared its Investigational New Drug application for UGN-501, an oncolytic virus intended for a Phase 1 trial in non-muscle invasive bladder cancer. This clearance expands UroGen's pipeline beyond bladder cancer and diversifies its in", "url": "https://www.sahmcapital.com/news/content/urogen-pharma-urgn-is-up-58-after-fda-clears-ind-for-ugn-501-phase-1-trial-2026-07-10", "source_name": "Sahm", "published_at": "2026-07-11T14:09:31", "published_display": "11 Jul 2026 14:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UroGen Pharma CMO Mark Schoenberg sells $400,000 in shares", "summary": "Mark Schoenberg, Chief Medical Officer of UroGen Pharma (NASDAQ:URGN), sold 10,000 ordinary shares for $400,000 on July 9, 2026, at an average price of $40.00 per share. This sale, executed under a pre-arranged trading plan, occurred as the stock traded near its 52-week high afte", "url": "https://www.investing.com/news/insider-trading-news/urogen-pharma-cmo-mark-schoenberg-sells-400000-in-shares-93CH-4786659", "source_name": "Investing.com", "published_at": "2026-07-10T18:10:31", "published_display": "10 Jul 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Urogen Pharma Ltd For: 10 July By Investing.com", "summary": "This Investing.com article is a brief financial notice indicating a Form 4 filing for Urogen Pharma Ltd on July 10. Such filings typically report changes in ownership of company securities by insiders. The article includes the stock symbol URGN and notes a -4.15% change.", "url": "https://ca.investing.com/news/stock-market-news/form-4-urogen-pharma-ltd-for-10-july-93CH-4729648", "source_name": "Investing.com Canada", "published_at": "2026-07-10T18:10:31", "published_display": "10 Jul 2026 18:10", "sentiment": "negative", "sentiment_pct": 41, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UroGen Pharma (URGN) CMO Mark Schoenberg sells 10,000 shares via Rule 10b5-1 plan", "summary": "UroGen Pharma's Chief Medical Officer, Mark Schoenberg, sold 10,000 Ordinary Shares of URGN at a weighted average price of $40.00 per share. This transaction was conducted under a pre-established Rule 10b5-1(c) trading plan adopted on August 15, 2025, and represents the final sal", "url": "https://www.stocktitan.net/sec-filings/URGN/form-4-uro-gen-pharma-ltd-insider-trading-activity-c7a769859983.html", "source_name": "Stock Titan", "published_at": "2026-07-10T18:10:31", "published_display": "10 Jul 2026 18:10", "sentiment": "negative", "sentiment_pct": 35, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is UroGen Pharma (URGN) Undervalued Following FDA Clearance For UGN 501?", "summary": "UroGen Pharma (URGN) is gaining investor attention after the FDA cleared its Investigational New Drug application for UGN-501, allowing a Phase 1 trial for non-muscle invasive bladder cancer. The company's stock has seen significant momentum, with a 1-year return of 175.38%. Whil", "url": "https://www.sahmcapital.com/news/content/is-urogen-pharma-urgn-undervalued-following-fda-clearance-for-ugn-501-2026-07-09", "source_name": "Sahm", "published_at": "2026-07-10T15:39:29", "published_display": "10 Jul 2026 15:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(URGN) Price Dynamics and Execution-Aware Positioning", "summary": "This article analyzes Urogen Pharma Ltd. (NASDAQ: URGN) stock dynamics, identifying strong sentiment across all horizons and significant upside potential due to the absence of resistance levels above the current price. It presents three AI-generated trading strategies\u2014Position Tr", "url": "https://news.stocktradersdaily.com/news_release/21/URGN_Price_Dynamics_and_Execution-Aware_Positioning_071026014402_1783705442.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-10T14:10:31", "published_display": "10 Jul 2026 14:10", "sentiment": "positive", "sentiment_pct": 80, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 UroGen Pharma Ltd. For: 9 July By Investing.com", "summary": "This article announces the filing of Form 144 for UroGen Pharma Ltd. on July 9th. It is a brief, technical notification from Investing.com, accompanied by standard financial market data and unrelated trending articles below the main content. The core purpose is to inform stakehol", "url": "https://ca.investing.com/news/stock-market-news/form-144-urogen-pharma-ltd-for-9-july-93CH-4728223", "source_name": "Investing.com Canada", "published_at": "2026-07-09T21:17:45", "published_display": "09 Jul 2026 21:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Affiliate files Form 144: UroGen (NASDAQ: URGN) sells two 10,000-share blocks", "summary": "UroGen Pharma Ltd. (NASDAQ: URGN) had two 10,000-share blocks of common stock sold by an affiliate on May 8, 2026, and June 22, 2026, for $300,048 and $350,143, respectively. These dispositions were reported via a Form 144 filing and involved an affiliate, Mark Schoenberg, with R", "url": "https://www.stocktitan.net/sec-filings/URGN/144-uro-gen-pharma-ltd-sec-filing-36a505a328d0.html", "source_name": "Stock Titan", "published_at": "2026-07-09T20:00:45", "published_display": "09 Jul 2026 20:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Urogen Pharma stock hits 52-week high at $39.59", "summary": "Urogen Pharma (URGN) stock has reached a new 52-week high of $39.59, reflecting a 175% increase over the past year and strong investor confidence. Despite a 53% revenue surge and nearly 90% gross profit margins, InvestingPro analysis indicates the stock may be overvalued. Recent ", "url": "https://www.investing.com/news/company-news/urogen-pharma-stock-hits-52week-high-at-3959-93CH-4784684", "source_name": "Investing.com", "published_at": "2026-07-09T19:00:45", "published_display": "09 Jul 2026 19:00", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UroGen wins FDA clearance to test bladder cancer virus in Phase 1", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNNkVaRWZMNkVSUF82U3JQWUNTVk1QbkZVckFGOXpmdlA2N0JSeTI4MlNZcTVBWFNLczI3NVhueFFBbTJFOUVVbWVSLTBOcHVoaUpQUXJDakttNDdjVGhjNFBQMW5BbmhrRms5blpfRllfRnhEYXAxVC1CY0RyWG1zM0xYakhtb2xZbzhZZEx5MzZ1WXc1VHJyRWFjWHUzSVZmejl6ZzV5VWxQT01DRG1hcTVn?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-08T07:00:00+00:00", "published_display": "08 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Urogen Pharma (URGN) is a Great Momentum Stock: Should You Buy?", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxNUnpKaXZhcjRUdFFGTENlRy1HV1lKNzJfMXFwVFI0R2tVcExKaVdDTmpLenM0cXd0SzNUT3NnQU5SeXIxejJRRzhWZV90VW94R3NQTXZJa09oeElfQzBXUC1qMXVYaEdRV29WUkpFZXdtQWp5M005UXdCSHoxNUVHZFMxWWlTeElqYlNvS3dCdFRLby1qb252TE5yZVA4VG8?oc=5", "source_name": "Market source", "published_at": "2026-07-07T07:00:00+00:00", "published_display": "07 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UroGen Pharma (URGN) Stock Looks Overvalued As 257% Returns Raise The Bar", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Let Go of 10,000 Shares?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxNR1dOWHp1VkdjSDMyN2hUQmNLTWYwblpESVpNU2x2QkdORUNsWG1mTGJqTmVLdWVVTm5LbDNGVXp1SFZIaHZOSTQySGtNdGs0VFVGMG1DeEVVUDNnQWZldEpKMm1UUjhNQ1VXcS1DNGVPWEdSN2kxcTB0bGlTci1ZLS03a182VnJZaDBuTlp6UjhDc0h1TUZDdzNBTQ?oc=5", "source_name": "Market source", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UroGen Pharma (URGN) director receives 20,000 stock options at $34.99 strike", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxPU3c4b1Q5bzlnN1kzUXcwUlROQXVLMEJPNUN0RklFY3BybDVUa2tSQUl2Tzh5QlhyVXFEMzdrXzh6VHlOU1R5OUN0X3hKQzZyZmFlcVNjVEdhU2dQcDhiel95WUEzWHRHaE1za1FRSU0tSEtWT2Y1eUktY0RTS1hlLVQzajR4bmRiUXQtSWlBd043aU91Rl9DdzZZck13OEctOHJpb1loLURtYXNUUXFvT3FB?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UroGen Pharma (URGN) CMO sells 10,000 shares in planned open-market trade", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNT2JNVFJNb2JMLVVXbmJFUFB2Z2dEeU95akhNdzNVU19RVUNMY2xwa3hMUVB4c1JmRGJaMkV2RmhQNmZ1RUhGbFFCeUxnUkRpbFVmaXFjVFVSVXQzU0FOMHdmZC10Mkc4Ry1MUGxzdUtBel9RSU1zcUhPX09kNE84OWdOSEgydUVaR0laQWxSVTVKVmRTeDFYaE1mY0RNbllmaVQzdVhsZ2FrTFNRN0hrUUJB?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UroGen Pharma (NASDAQ: URGN) OKs new articles and equity plan share increase", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxQSnRKTTNnd25rcjZpSmJydDZ0OTduUlBXcUdxcU9aYWtBRDBOMFUyYUF1U3lsVXVUY1FaSmZBZ2V1RG5QQnhtSTVNY29qVk9IMHYtY1BpTlZWYVBpY0dPY2puQzYzQW9GN0lqVXl4NU5mYXFwU2J0Y1lfNGM0RUhkdGotcTVNOWdBSVdyOWk2UHdIQjFJTmpCVlJDVXp0V2lsTE96UDdHamxUU0E?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UroGen Pharma (URGN) Form 144: Director sale of 10,000 shares for $300K", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxORzlNTlV1Zkx5aDNCTUlZenlleGRKZEtLYmFkXzFVd05Id3E2TkFGbnZVTGVFM1prVUNaV0VjalJlRU04b0NaRlVuUGN0c3hwcWFWTWRfUWxwa1NCdWdEOUlMUXBYSldmZ1BfQzFPZVdJa3JVdjZEdy1JZ3JzeWtNWU5DUk1jZkZPYmRldVBPcGpXU3lkTmVrQkc0WQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mark Schoeberg sells 10,000 shares of UroGen (URGN) reported in Form 144", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxNbGwxRV9jeTNuN2hUT3NXUFMwYl9wSHVNaXJ4b1Mxdk5OSEpPOElmRVJrUncxOWZvaC1OVFotVWFOZnphRDBXZGpWQVJvbUc4ellDa0NxalNjc2NwRGhPYlFHRGJFdW5LeGJJWXR4dG8xQURZOFl1LU4zZE9ZSFRzVzZIMXBhVVo2QXlqTWxUM2N0UXphcXFWblM5WQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UroGen Pharma (URGN) Settles Patent Dispute with Teva Pharmaceuticals (TEVA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxOZklOeWtWWk1CeV9xV0ZjLTNBdmVCU3dEZ3QxOVRzLUsxV0YwekhLLWNtakJsS2VXWHBJbEVqSjlDUWpzMV9mM01hVjRLNDc4UHR6RUxOWjUtQ3RXUjc0ZksyR2I1bDFkU01NS1poS21TWkxpb3J6cEZiUmx5Vmd4Q3kybENqUHlMaWxYN0VFTDRJU1EwbGx2NHFxakt2QTlDaDZwYzVWOVQ0bWI1UUdTeU10cEJMbzJfN0Jid0hlWHk2NnQ1TW45eFFWRGxsblBuUUFBMDczeUh4X09TcTRrWGlaeG9xZw?oc=5", "source_name": "GuruFocus", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Hear UroGen\u2019s Goldman Sachs healthcare chat online with 90-day replay", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPb1p1enRUMU9PRXZWdDRGV1VqUjVNelo5NVRNc1F5MTdDR3llSmpLWkI3a3ZDZWt1WXB4UkQxb2hWRTc2RXdiclMwYnh0QjRWeU04UzlmbnhJbUVSSzJValBOak5rQ0pfY2ZRMTB6WElGcXdObGNlQkI0RzFiSmM0QTVqU3lxXzBOdm1weVhMMmlJR2Y4VGs1QVVTRDBGVXFUM0c3Nk9DQXF4Y3hrNG5wbTRBVmhvdTBuMVBjTQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Assessing UroGen Pharma (URGN) Valuation After Q1 2026 Earnings Beat And Zusduri Launch Momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQaWFYczZvMl83SVBFSGg0d0R3aXlxU0lZdUhFZTdDYzE3WmJjSkFwTUxCNjVQblMtVzcyWnVkTEJSSzhldEdPb3lWc01mODVHdjRiNWJ6QWZ4V0ZKVC1EMkdfdjJIYVN0MW1laTJNVzJaTGFwN2E4Q2dYcmtqWkVMNGpIaTNEcDE2YmQyaUk0UWN2VXZjenRxUENPZ3hmOE5JaWJaT1ln?oc=5", "source_name": "Market source", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "How UroGen Pharma (URGN) Narrative Is Evolving Around Fair Value Risks And Opportunities", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxOVVFvX25VUjk0cl9uWE1ib1ZNemdISGVUbnc5WEpwSHZ0Ry12RHU4R2F3a0JVdWZJemFfaDk5dUlsTGJ4M1JXaWViR0dZM2IwY1RPZEFqTjhKWkphTWFVNno3bENuc1ViS2J6Qk1GVmRfaWxDLU5Pa0MzZHdZSV80aDFsOUphanlkbDhtOHZPNFEyZDVVUWotUmFlVkd3U3I5UnhkSg?oc=5", "source_name": "Market source", "published_at": "2026-03-20T07:00:00+00:00", "published_display": "20 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Multiple Insiders Sold UroGen Pharma Shares Presenting Weak Signs For Investors", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-07T08:00:00+00:00", "published_display": "07 Jan 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UroGen Pharma Ltd. (NASDAQ:URGN) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-05T08:00:00+00:00", "published_display": "05 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "URGN stock trades steady as UroGen revenue grows and pipeline advances", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxPUzdKQ3F3dDZEMWV0dnJqVkpSX3NYd25PUkd3dW44NVlnUEV3Q1FfREs4WU1GZzBHTHdENHRYRjNnSGZTV3lYTFNLbkstOWNvMEZ6MTAzUWF2ZkdfampTY0FmWE5Yc2NicXZuZExpMlNDMjdXbEUwenlMbk9VTmg0V0RaY2lNSGt4cGVOZW8tR1ZfWFZERWVhOWRRS2d4d0prOXRzV1NsTTlrWVJ4RG5hbVJoYjR0LVVic21oVk50VDgzaFF0LVFxQg?oc=5", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-21T11:27:30+00:00", "published_display": "21 Jul 2026 11:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What UroGen Pharma (URGN)'s UGN-501 IND Clearance Means For Shareholders", "summary": "UroGen Pharma received IND clearance for UGN-501, an oncolytic virus for non-muscle invasive bladder cancer, allowing a Phase 1 trial to commence. While this expands their pipeline, the company's near-term focus remains on the uptake of ZUSDURI and the regulatory path for UGN-103", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-urgn/urogen-pharma/news/what-urogen-pharma-urgns-ugn-501-ind-clearance-means-for-sha", "source_name": "Simply Wall Street", "published_at": "2026-07-21T05:12:14", "published_display": "21 Jul 2026 05:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of UroGen Pharma Ltd. \u2013 MUN:UR8", "summary": "This article focuses on the \"Price to sales forward\" financial metric for UroGen Pharma Ltd. (MUN:UR8) available on TradingView. It appears to be a financial data snippet or a specific data point rather than a detailed analytical article. The content is primarily a listing of fin", "url": "https://www.tradingview.com/symbols/MUN-UR8/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-21T02:09:58", "published_display": "21 Jul 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of UroGen Pharma Ltd. \u2013 NASDAQ:URGN", "summary": "This article provides a brief financial update for UroGen Pharma Ltd. (NASDAQ: URGN), specifically focusing on its forward price-to-sales ratio. It indicates that the market was closed with no trades recorded at the time of the report. The content appears to be a stub or a placeh", "url": "https://www.tradingview.com/symbols/NASDAQ-URGN/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-21T00:12:14", "published_display": "21 Jul 2026 00:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UroGen Pharma: Reimbursement Is Turning Zusduri Into A Workflow Moat (NASDAQ:URGN)", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxOR1RQLUpKWnAtMHpDcUZuN2tHZzR0SXplS0xWVTVPUDQ4QUttNExwU2xNN1FMUlBocTFTNElrbUZlRU1iWHlnZ2Nnc25lVXFjZ1l0bzltTkNVYnZOTEhPODFOVWdldkRDNHNkTnR3ZmMtaGVuSkdaQWI4MDA1R0x1V3B6a2YyOW5UUklZWE5CempYS3Q3OXYtbWJSMnlQRXgyZWs2Y3BXVmZjWXhm?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-20T18:07:04+00:00", "published_display": "20 Jul 2026 18:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UroGen Pharma (URGN) AGM 2026 Summary", "summary": "UroGen Pharma's 2026 AGM highlighted the successful launch of ZUSDURI, a new FDA-approved bladder cancer treatment, and continued growth of JELMYTO. The meeting also addressed the advancement of pipeline products like UGN-103, UGN-104, and UGN-501, and nominated seven directors f", "url": "https://quartr.com/events/urogen-pharma-ltd-urgn-agm-2026_F3zJeaCg", "source_name": "Quartr", "published_at": "2026-07-20T02:09:58", "published_display": "20 Jul 2026 02:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UroGen Pharma (URGN) Rallies On FDA Clearance As Valuation Questions Grow", "summary": "UroGen Pharma (URGN) has rallied significantly following FDA clearance for its UGN-501, allowing a Phase 1 bladder cancer study. While the stock has seen impressive returns, current analyst narratives suggest it is overvalued at $36.11, despite a Simply Wall St DCF model indicati", "url": "https://www.sahmcapital.com/news/content/urogen-pharma-urgn-rallies-on-fda-clearance-as-valuation-questions-grow-2026-07-18", "source_name": "Sahm", "published_at": "2026-07-19T02:09:59", "published_display": "19 Jul 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What's Driving Investor Interest in UroGen Pharma (URGN) Ahead of Goldman Sachs", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNNEdGU1B4UmE0TUpkZ284Q212QmdqNTlaZkl0WWN1d1pRWFRncXNZbk9XbXRCSWFTc2FIOHhRSEFqYWc5Q25Ta0xTcE40R3Vqa0UxcmhNY09YaXVTZVJvUDR0cTVxai1scjVENTNfM282N3Z4bkNZRU5NOTBLX3JFSGdUY0pHRV8tTTBERXhJXzNNLXkxeDluc3lNcHlERll2NXFrZzd6dWJ4ZVFSclh0V21R?oc=5", "source_name": "Kavout | AI", "published_at": "2026-07-18T14:00:24+00:00", "published_display": "18 Jul 2026 14:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Urogen Pharma stock hits 52-week high at 41.45 USD", "summary": "Urogen Pharma's stock has reached a 52-week high of $41.45, reflecting strong investor confidence and significant year-to-date gains. The company has several positive developments, including an increased price target from Oppenheimer, a new patent for bladder cancer treatment, an", "url": "https://www.investing.com/news/company-news/urogen-pharma-stock-hits-52week-high-at-4145-usd-93CH-4798631", "source_name": "Investing.com", "published_at": "2026-07-18T13:41:46", "published_display": "18 Jul 2026 13:41", "sentiment": "positive", "sentiment_pct": 94, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Short Sellers Are Betting Against UroGen Pharma Stock, But Wall Street Expects 263% Earnings Growth in 2027", "summary": "UroGen Pharma (URGN) has experienced significant stock growth and strong technical indicators, with analysts predicting substantial revenue and earnings increases in the coming years. Despite this positive outlook and five years of revenue growth, the company remains unprofitable", "url": "https://www.barchart.com/story/news/3336887/short-sellers-are-betting-against-urogen-pharma-stock-but-wall-street-expects-263-earnings-growth-in-2027", "source_name": "Barchart.com", "published_at": "2026-07-18T09:15:00", "published_display": "18 Jul 2026 09:15", "sentiment": "positive", "sentiment_pct": 76, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Urogen Pharma stock hits 52-week high at 41.45 USD By Investing.com", "summary": "Urogen Pharma Ltd.'s stock reached a 52-week high of $41.45, now trading just under 1% below its peak with significant year-to-date and six-month returns. This surge follows positive developments including Oppenheimer raising its price target to $50, a patent allowance for bladde", "url": "https://m.za.investing.com/news/stock-market-news/urogen-pharma-stock-hits-52week-high-at-4145-usd-93CH-4374664?ampMode=1", "source_name": "Investing.com South Africa", "published_at": "2026-07-18T00:09:38", "published_display": "18 Jul 2026 00:09", "sentiment": "positive", "sentiment_pct": 94, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates UroGen Pharma stock rating on patent news", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxOTlBYdmZzYVF6dFdJUE9KSU5waU5MWXotS0NQeEtwaWRVSWljV0VMR3JBRUpnaXpQVkQyREw1NTcwalI0bUZWR285dll3VkFrWXNsU3h1cnQwdlJqaXdLbGtoYjNaY3RHX0txUVpKRUtITGFyMlh6NFdMYmNNMHRoRzZtRTBTN0hmWGEyNkJMMXFQdHVkeDZXNldaOU11SGN3VXdGUjAxVUMwc1JxVFM5X0k0T1U3SXl0ZGlfWGpaWFpyYWR1?oc=5", "source_name": "Investing.com", "published_at": "2026-07-16T11:58:03+00:00", "published_display": "16 Jul 2026 11:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oppenheimer raises UroGen Pharma stock price target to $50 on sales outlook", "summary": "Oppenheimer has increased its price target for UroGen Pharma (NASDAQ:URGN) to $50 from $40, maintaining an Outperform rating, based on increased sales projections for their Jelmyto product. The firm's updated estimates for Jelmyto sales in 2026-28 are $210 million, $448 million, ", "url": "https://www.investing.com/news/analyst-ratings/oppenheimer-raises-urogen-pharma-stock-price-target-to-50-on-sales-outlook-93CH-4795586", "source_name": "Investing.com", "published_at": "2026-07-16T11:58:09", "published_display": "16 Jul 2026 11:58", "sentiment": "positive", "sentiment_pct": 86, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates UroGen Pharma stock rating on patent news By Investing.com", "summary": "H.C. Wainwright has reiterated a Buy rating and a $45.00 price target for UroGen Pharma (NASDAQ:URGN) after the company received a Notice of Allowance for a patent related to treating low-grade intermediate-risk non-muscle-invasive bladder cancer. This patent, supported by data f", "url": "https://m.au.investing.com/news/stock-market-news/hc-wainwright-reiterates-urogen-pharma-stock-rating-on-patent-news-93CH-4536603?ampMode=1", "source_name": "Investing.com Australia", "published_at": "2026-07-16T11:39:29", "published_display": "16 Jul 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UroGen Pharma (URGN) Secures Patent Approval for Bladder Cancer Treatment", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxPTFh2bjZDcWNzaWpGLVc0VlYyM1M4RUkxb2dBT0g1QTlHM1NfUkhoNXdVeUFpOGM3S1k0YmVIeTZNcVBic0dEMFFvUVp6cE9LOTdxU0NVajhtaThaSlpFTld5MmVMLUtCUDFUQUdIM0M0bDI3a2p1U2QwYkd3b2dYX0F4WDlTT25zRzI0aGZiemw0MENlMHpRNDJzRmYzSDNBWDNtSzhWUUxPTG5semdaRTNtOVNBOERyRDk5Nl9FaGswUjlVTHVmU21Vcjg3elpKa1dLYmgzLUtkZUxPeldiMTM0YkU?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-16T10:11:24+00:00", "published_display": "16 Jul 2026 10:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Goldman Sachs Maintains UroGen Pharma Ltd(URGN.US) With Hold Rating, Raises Target Price to $44", "summary": "Goldman Sachs has reiterated its Hold rating on UroGen Pharma Ltd (URGN.US) and has increased its price target for the company's stock to $44. This adjustment reflects a continued neutral stance on the company's prospects while revising the expected valuation upwards.", "url": "https://www.moomoo.com/news/post/73032059/goldman-sachs-maintains-urogen-pharma-ltd-urgnus-with-hold-rating", "source_name": "Moomoo", "published_at": "2026-07-16T01:10:08", "published_display": "16 Jul 2026 01:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UroGen Pharma (URGN) Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary", "summary": "UroGen Pharma (URGN) presented at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026, highlighting its RTGel technology for sustained drug delivery in urothelial cancer. The company discussed the commercial success of its products, JELMYTO and ZUSDURI, with ZUSDURI's", "url": "https://quartr.com/events/urogen-pharma-urgn-guggenheim-securities-emerging-outlook-biotech-summit-2026_F3zJeILb", "source_name": "Quartr", "published_at": "2026-07-15T13:41:46", "published_display": "15 Jul 2026 13:41", "sentiment": "positive", "sentiment_pct": 75, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UroGen patent allowance covers bladder cancer care without tumor resection", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxPdExkdFJxSTdEVlgtVHpLVWtwc296VUJGZmtLdGFIcFlmYlpRbXhwMk1Obm53aklWZ2lPdEdwSjlBWHJHd0U4Vl9acmtZcmNEVE9xNV9DcnF0ZHNjQktZTEJIbTRub21aUFJaVGN5MU9fcl81X3R4b181Z1hPSW1GdW5NM0VzdFhVTHAwcndZNGtyZzJ3NVFSUnQ2cEplS2l6UU9Id2ZyMlc4U0hZN0RaUTBkbWQ2Mzg?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-15T12:00:00+00:00", "published_display": "15 Jul 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UroGen Receives New U.S. Patent Allowance Expected to Provide Protection into July 2044 for ZUSDURI\u2122 and UGN-103", "summary": "UroGen Pharma Ltd. announced it received a U.S. patent allowance extending protection for ZUSDURI\u2122 and investigational UGN-103 into July 2044. The patent covers methods for treating recurrent, low-grade intermediate-risk non-muscle-invasive bladder cancer without transurethral re", "url": "https://www.globenewswire.com/news-release/2026/07/15/3327670/0/en/urogen-receives-new-u-s-patent-allowance-expected-to-provide-protection-into-july-2044-for-zusduri-and-ugn-103.html", "source_name": "GlobeNewswire", "published_at": "2026-07-15T12:15:29", "published_display": "15 Jul 2026 12:15", "sentiment": "positive", "sentiment_pct": 74, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UroGen Announces FDA Clearance of the IND for UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer", "summary": "UroGen Pharma Ltd. announced that the FDA has cleared its Investigational New Drug (IND) application for UGN-501, a next-generation oncolytic virus for non-muscle invasive bladder cancer (NMIBC). This clearance allows the company to initiate a Phase 1 clinical study in Q4 2026 to", "url": "https://biobuzz.io/news/urogen-announces-fda-clearance-of-the-ind-for-ugn-501-an-investigational-next-generation-oncolytic-virus-for-non-muscle-invasive-bladder-cancer/", "source_name": "BioBuzz", "published_at": "2026-07-15T00:15:30", "published_display": "15 Jul 2026 00:15", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UroGen's Chief Medical Officer Sold $400,000 in Stock After a 191% Run", "summary": "UroGen Pharma's Chief Medical Officer, Mark Schoenberg, sold 10,000 shares worth $400,000 as the final transaction of a pre-established 10b5-1 trading plan. Despite the sale, Schoenberg retains a significant stake of nearly $4.8 million in the company. The article notes this tran", "url": "https://finance.yahoo.com/markets/stocks/articles/urogens-chief-medical-officer-sold-183156914.html", "source_name": "Market source", "published_at": "2026-07-13T11:41:25", "published_display": "13 Jul 2026 11:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UroGen Pharma (URGN) Is Up 5.8% After FDA Clears IND For UGN-501 Phase 1 Trial", "summary": "UroGen Pharma's stock rose 5.8% after the FDA cleared its Investigational New Drug application for UGN-501, an oncolytic virus intended for a Phase 1 trial in non-muscle invasive bladder cancer. This clearance expands UroGen's pipeline beyond bladder cancer and diversifies its in", "url": "https://www.sahmcapital.com/news/content/urogen-pharma-urgn-is-up-58-after-fda-clears-ind-for-ugn-501-phase-1-trial-2026-07-10", "source_name": "Sahm", "published_at": "2026-07-11T14:09:31", "published_display": "11 Jul 2026 14:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UroGen Pharma CMO Mark Schoenberg sells $400,000 in shares", "summary": "Mark Schoenberg, Chief Medical Officer of UroGen Pharma (NASDAQ:URGN), sold 10,000 ordinary shares for $400,000 on July 9, 2026, at an average price of $40.00 per share. This sale, executed under a pre-arranged trading plan, occurred as the stock traded near its 52-week high afte", "url": "https://www.investing.com/news/insider-trading-news/urogen-pharma-cmo-mark-schoenberg-sells-400000-in-shares-93CH-4786659", "source_name": "Investing.com", "published_at": "2026-07-10T18:10:31", "published_display": "10 Jul 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Urogen Pharma Ltd For: 10 July By Investing.com", "summary": "This Investing.com article is a brief financial notice indicating a Form 4 filing for Urogen Pharma Ltd on July 10. Such filings typically report changes in ownership of company securities by insiders. The article includes the stock symbol URGN and notes a -4.15% change.", "url": "https://ca.investing.com/news/stock-market-news/form-4-urogen-pharma-ltd-for-10-july-93CH-4729648", "source_name": "Investing.com Canada", "published_at": "2026-07-10T18:10:31", "published_display": "10 Jul 2026 18:10", "sentiment": "negative", "sentiment_pct": 41, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UroGen Pharma (URGN) CMO Mark Schoenberg sells 10,000 shares via Rule 10b5-1 plan", "summary": "UroGen Pharma's Chief Medical Officer, Mark Schoenberg, sold 10,000 Ordinary Shares of URGN at a weighted average price of $40.00 per share. This transaction was conducted under a pre-established Rule 10b5-1(c) trading plan adopted on August 15, 2025, and represents the final sal", "url": "https://www.stocktitan.net/sec-filings/URGN/form-4-uro-gen-pharma-ltd-insider-trading-activity-c7a769859983.html", "source_name": "Stock Titan", "published_at": "2026-07-10T18:10:31", "published_display": "10 Jul 2026 18:10", "sentiment": "negative", "sentiment_pct": 35, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is UroGen Pharma (URGN) Undervalued Following FDA Clearance For UGN 501?", "summary": "UroGen Pharma (URGN) is gaining investor attention after the FDA cleared its Investigational New Drug application for UGN-501, allowing a Phase 1 trial for non-muscle invasive bladder cancer. The company's stock has seen significant momentum, with a 1-year return of 175.38%. Whil", "url": "https://www.sahmcapital.com/news/content/is-urogen-pharma-urgn-undervalued-following-fda-clearance-for-ugn-501-2026-07-09", "source_name": "Sahm", "published_at": "2026-07-10T15:39:29", "published_display": "10 Jul 2026 15:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(URGN) Price Dynamics and Execution-Aware Positioning", "summary": "This article analyzes Urogen Pharma Ltd. (NASDAQ: URGN) stock dynamics, identifying strong sentiment across all horizons and significant upside potential due to the absence of resistance levels above the current price. It presents three AI-generated trading strategies\u2014Position Tr", "url": "https://news.stocktradersdaily.com/news_release/21/URGN_Price_Dynamics_and_Execution-Aware_Positioning_071026014402_1783705442.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-10T14:10:31", "published_display": "10 Jul 2026 14:10", "sentiment": "positive", "sentiment_pct": 80, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 UroGen Pharma Ltd. For: 9 July By Investing.com", "summary": "This article announces the filing of Form 144 for UroGen Pharma Ltd. on July 9th. It is a brief, technical notification from Investing.com, accompanied by standard financial market data and unrelated trending articles below the main content. The core purpose is to inform stakehol", "url": "https://ca.investing.com/news/stock-market-news/form-144-urogen-pharma-ltd-for-9-july-93CH-4728223", "source_name": "Investing.com Canada", "published_at": "2026-07-09T21:17:45", "published_display": "09 Jul 2026 21:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Affiliate files Form 144: UroGen (NASDAQ: URGN) sells two 10,000-share blocks", "summary": "UroGen Pharma Ltd. (NASDAQ: URGN) had two 10,000-share blocks of common stock sold by an affiliate on May 8, 2026, and June 22, 2026, for $300,048 and $350,143, respectively. These dispositions were reported via a Form 144 filing and involved an affiliate, Mark Schoenberg, with R", "url": "https://www.stocktitan.net/sec-filings/URGN/144-uro-gen-pharma-ltd-sec-filing-36a505a328d0.html", "source_name": "Stock Titan", "published_at": "2026-07-09T20:00:45", "published_display": "09 Jul 2026 20:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Urogen Pharma stock hits 52-week high at $39.59", "summary": "Urogen Pharma (URGN) stock has reached a new 52-week high of $39.59, reflecting a 175% increase over the past year and strong investor confidence. Despite a 53% revenue surge and nearly 90% gross profit margins, InvestingPro analysis indicates the stock may be overvalued. Recent ", "url": "https://www.investing.com/news/company-news/urogen-pharma-stock-hits-52week-high-at-3959-93CH-4784684", "source_name": "Investing.com", "published_at": "2026-07-09T19:00:45", "published_display": "09 Jul 2026 19:00", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UroGen wins FDA clearance to test bladder cancer virus in Phase 1", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNNkVaRWZMNkVSUF82U3JQWUNTVk1QbkZVckFGOXpmdlA2N0JSeTI4MlNZcTVBWFNLczI3NVhueFFBbTJFOUVVbWVSLTBOcHVoaUpQUXJDakttNDdjVGhjNFBQMW5BbmhrRms5blpfRllfRnhEYXAxVC1CY0RyWG1zM0xYakhtb2xZbzhZZEx5MzZ1WXc1VHJyRWFjWHUzSVZmejl6ZzV5VWxQT01DRG1hcTVn?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-08T07:00:00+00:00", "published_display": "08 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Urogen Pharma (URGN) is a Great Momentum Stock: Should You Buy?", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxNUnpKaXZhcjRUdFFGTENlRy1HV1lKNzJfMXFwVFI0R2tVcExKaVdDTmpLenM0cXd0SzNUT3NnQU5SeXIxejJRRzhWZV90VW94R3NQTXZJa09oeElfQzBXUC1qMXVYaEdRV29WUkpFZXdtQWp5M005UXdCSHoxNUVHZFMxWWlTeElqYlNvS3dCdFRLby1qb252TE5yZVA4VG8?oc=5", "source_name": "Market source", "published_at": "2026-07-07T07:00:00+00:00", "published_display": "07 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UroGen Pharma (URGN) Stock Looks Overvalued As 257% Returns Raise The Bar", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Let Go of 10,000 Shares?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxNR1dOWHp1VkdjSDMyN2hUQmNLTWYwblpESVpNU2x2QkdORUNsWG1mTGJqTmVLdWVVTm5LbDNGVXp1SFZIaHZOSTQySGtNdGs0VFVGMG1DeEVVUDNnQWZldEpKMm1UUjhNQ1VXcS1DNGVPWEdSN2kxcTB0bGlTci1ZLS03a182VnJZaDBuTlp6UjhDc0h1TUZDdzNBTQ?oc=5", "source_name": "Market source", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UroGen Pharma (URGN) director receives 20,000 stock options at $34.99 strike", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxPU3c4b1Q5bzlnN1kzUXcwUlROQXVLMEJPNUN0RklFY3BybDVUa2tSQUl2Tzh5QlhyVXFEMzdrXzh6VHlOU1R5OUN0X3hKQzZyZmFlcVNjVEdhU2dQcDhiel95WUEzWHRHaE1za1FRSU0tSEtWT2Y1eUktY0RTS1hlLVQzajR4bmRiUXQtSWlBd043aU91Rl9DdzZZck13OEctOHJpb1loLURtYXNUUXFvT3FB?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UroGen Pharma (URGN) CMO sells 10,000 shares in planned open-market trade", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNT2JNVFJNb2JMLVVXbmJFUFB2Z2dEeU95akhNdzNVU19RVUNMY2xwa3hMUVB4c1JmRGJaMkV2RmhQNmZ1RUhGbFFCeUxnUkRpbFVmaXFjVFVSVXQzU0FOMHdmZC10Mkc4Ry1MUGxzdUtBel9RSU1zcUhPX09kNE84OWdOSEgydUVaR0laQWxSVTVKVmRTeDFYaE1mY0RNbllmaVQzdVhsZ2FrTFNRN0hrUUJB?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UroGen Pharma (NASDAQ: URGN) OKs new articles and equity plan share increase", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxQSnRKTTNnd25rcjZpSmJydDZ0OTduUlBXcUdxcU9aYWtBRDBOMFUyYUF1U3lsVXVUY1FaSmZBZ2V1RG5QQnhtSTVNY29qVk9IMHYtY1BpTlZWYVBpY0dPY2puQzYzQW9GN0lqVXl4NU5mYXFwU2J0Y1lfNGM0RUhkdGotcTVNOWdBSVdyOWk2UHdIQjFJTmpCVlJDVXp0V2lsTE96UDdHamxUU0E?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UroGen Pharma (URGN) Form 144: Director sale of 10,000 shares for $300K", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxORzlNTlV1Zkx5aDNCTUlZenlleGRKZEtLYmFkXzFVd05Id3E2TkFGbnZVTGVFM1prVUNaV0VjalJlRU04b0NaRlVuUGN0c3hwcWFWTWRfUWxwa1NCdWdEOUlMUXBYSldmZ1BfQzFPZVdJa3JVdjZEdy1JZ3JzeWtNWU5DUk1jZkZPYmRldVBPcGpXU3lkTmVrQkc0WQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mark Schoeberg sells 10,000 shares of UroGen (URGN) reported in Form 144", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxNbGwxRV9jeTNuN2hUT3NXUFMwYl9wSHVNaXJ4b1Mxdk5OSEpPOElmRVJrUncxOWZvaC1OVFotVWFOZnphRDBXZGpWQVJvbUc4ellDa0NxalNjc2NwRGhPYlFHRGJFdW5LeGJJWXR4dG8xQURZOFl1LU4zZE9ZSFRzVzZIMXBhVVo2QXlqTWxUM2N0UXphcXFWblM5WQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UroGen Pharma (URGN) Settles Patent Dispute with Teva Pharmaceuticals (TEVA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxOZklOeWtWWk1CeV9xV0ZjLTNBdmVCU3dEZ3QxOVRzLUsxV0YwekhLLWNtakJsS2VXWHBJbEVqSjlDUWpzMV9mM01hVjRLNDc4UHR6RUxOWjUtQ3RXUjc0ZksyR2I1bDFkU01NS1poS21TWkxpb3J6cEZiUmx5Vmd4Q3kybENqUHlMaWxYN0VFTDRJU1EwbGx2NHFxakt2QTlDaDZwYzVWOVQ0bWI1UUdTeU10cEJMbzJfN0Jid0hlWHk2NnQ1TW45eFFWRGxsblBuUUFBMDczeUh4X09TcTRrWGlaeG9xZw?oc=5", "source_name": "GuruFocus", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Hear UroGen\u2019s Goldman Sachs healthcare chat online with 90-day replay", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPb1p1enRUMU9PRXZWdDRGV1VqUjVNelo5NVRNc1F5MTdDR3llSmpLWkI3a3ZDZWt1WXB4UkQxb2hWRTc2RXdiclMwYnh0QjRWeU04UzlmbnhJbUVSSzJValBOak5rQ0pfY2ZRMTB6WElGcXdObGNlQkI0RzFiSmM0QTVqU3lxXzBOdm1weVhMMmlJR2Y4VGs1QVVTRDBGVXFUM0c3Nk9DQXF4Y3hrNG5wbTRBVmhvdTBuMVBjTQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing UroGen Pharma (URGN) Valuation After Q1 2026 Earnings Beat And Zusduri Launch Momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQaWFYczZvMl83SVBFSGg0d0R3aXlxU0lZdUhFZTdDYzE3WmJjSkFwTUxCNjVQblMtVzcyWnVkTEJSSzhldEdPb3lWc01mODVHdjRiNWJ6QWZ4V0ZKVC1EMkdfdjJIYVN0MW1laTJNVzJaTGFwN2E4Q2dYcmtqWkVMNGpIaTNEcDE2YmQyaUk0UWN2VXZjenRxUENPZ3hmOE5JaWJaT1ln?oc=5", "source_name": "Market source", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How UroGen Pharma (URGN) Narrative Is Evolving Around Fair Value Risks And Opportunities", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxOVVFvX25VUjk0cl9uWE1ib1ZNemdISGVUbnc5WEpwSHZ0Ry12RHU4R2F3a0JVdWZJemFfaDk5dUlsTGJ4M1JXaWViR0dZM2IwY1RPZEFqTjhKWkphTWFVNno3bENuc1ViS2J6Qk1GVmRfaWxDLU5Pa0MzZHdZSV80aDFsOUphanlkbDhtOHZPNFEyZDVVUWotUmFlVkd3U3I5UnhkSg?oc=5", "source_name": "Market source", "published_at": "2026-03-20T07:00:00+00:00", "published_display": "20 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Multiple Insiders Sold UroGen Pharma Shares Presenting Weak Signs For Investors", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-07T08:00:00+00:00", "published_display": "07 Jan 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UroGen Pharma Ltd. (NASDAQ:URGN) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-05T08:00:00+00:00", "published_display": "05 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 89, "total_relevant": 54, "sentiment_summary": {"positive": 16, "negative": 6, "neutral": 32, "score": 57, "total": 54, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 78, "events": [{"event": "general", "label": "Market update", "weight": 14.65, "count": 26}, {"event": "earnings", "label": "Earnings", "weight": 5.91, "count": 13}, {"event": "analyst", "label": "Analyst action", "weight": 3.85, "count": 7}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 3.3, "count": 6}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}], "positive_events": 16, "negative_events": 6}, "market_context": {"has_market_context": true, "latest_close": 40.23, "latest_week": "2026-07-17", "one_week_move": 4.3, "four_week_move": 19.8, "twelve_week_move": 66.9, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.341611, "market_dynamics_buy_signal": false, "relative_strength": 58.948596, "fair_value_gap": 140.8, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 48.076, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+4.3% over one week, +19.8% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 66, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 11}, {"label": "Stock Titan", "count": 10}, {"label": "Investing.com", "count": 5}, {"label": "simplywall.st", "count": 5}, {"label": "TradingView", "count": 3}, {"label": "Sahm", "count": 3}, {"label": "Quartr", "count": 2}, {"label": "GuruFocus", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 45}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 26}, {"label": "Earnings", "count": 13}, {"label": "Analyst action", "count": 7}, {"label": "Regulatory and legal", "count": 6}, {"label": "Guidance", "count": 1}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "57/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "78/100 classification confidence."}, {"label": "Company focus", "value": "45", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+4.3% over one week, +19.8% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "URGN stock trades steady as UroGen revenue grows and pipeline advances"}], "updated_at": "2026-07-22T05:12:42.941017+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}